{"id":"NCT00731120","sponsor":"Takeda","briefTitle":"Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-01","completion":"2009-02","firstPosted":"2008-08-08","resultsPosted":"2013-12-18","lastUpdate":"2013-12-18"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","BrintellixÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine 2.5 mg","type":"EXPERIMENTAL"},{"label":"Vortioxetine 10 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-9.87,"sd":0.584},{"arm":"Vortioxetine 2.5 mg","deltaMin":-10.75,"sd":0.569},{"arm":"Vortioxetine 10 mg","deltaMin":-10.68,"sd":0.581}],"pValues":[{"comp":"OG000 vs OG001","p":"0.279"},{"comp":"OG000 vs OG002","p":"0.306"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["24424707"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["Nausea","Headache","Dry mouth","Diarrhoea","Constipation"]}}